(VIANEWS) – Shares of TARGOVAX (Oslo Børs All-share Index_GI: TRVX.OL) jumped by a staggering 17.91% to kr1.20 at 10:44 EST on Thursday, following the last session’s downward trend. Oslo Børs All-share Index_GI is jumping 0.1% to kr1,414.92, after five successive sessions in a row of losses. This seems, up until now, a somewhat up trend trading session today.
About TARGOVAX
Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.
Earnings Per Share
As for profitability, TARGOVAX has a trailing twelve months EPS of kr-1.402.
Volatility
TARGOVAX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.73%, a negative 0.60%, and a positive 2.15%.
TARGOVAX’s highest amplitude of average volatility was 1.86% (last week), 1.98% (last month), and 2.15% (last quarter).
Volume
Today’s last reported volume for TARGOVAX is 5982559 which is 1283.27% above its average volume of 432493.
More news about TARGOVAX (TRVX.OL).
